The current status of lipid-lowering therapy in patients with coronary heart disease
- VernacularTitle:冠心病降脂治疗101例分析
- Author:
Wen YAN
;
Shuiping ZHAO
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
Lipid-lowering therapy;
Low density lipoprotein cholesterol
- From:
Chinese Journal of Practical Internal Medicine
2006;0(16):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the plasma lipid levels,ratio achieving the optimal goals and its possible influencing factors in patients with coronary heart disease,and to elaborate the current status of lipid-lowering therapy.Methods The incipient plasma lipid level and status of therapy from the case history data of the 101 patients with CHD who were followed up after discharge were collected.The data including blood lipid levels and medications were recorded and analyzed.Results (1)60.6%patients with CHD had elevated LDL-C,but actually 80.7% had taken lipid-lowering drugs in hospital.(2)Lipid-lowering therapy was used in 68.3% of patients during the follow-up period.According to NCEP ATP Ⅲ,the ratio achieving the optimal LDL-C goals was 65.3%.(3)The ratio achieving the optimal goals was related to income and smoking(P0.05).(4)None of the patients had apparent elevated alanine aminotransferase(ALT)or creatine kinase(CK).Conclusion The current status of CHD lipid-lowering therapy remains a big gap.The ratio achieving the optimal goals is related to economy status and life style(smoking),and influenced by the physician quality of care,patient compliance,drug efficacy and cost–benefit.Long-term lipid-lowering therapy is safe when the drug use and dosage are appropriate.
